{"organizations": [], "uuid": "1f58883ac1f510d69db5f72d7278ca93e9768023", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180305.html", "section_title": "Archive News &amp; Video for Monday, 05 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-recipharm-signs-licensing-agreemen/brief-recipharm-signs-licensing-agreement-with-altus-formulation-idUSASM000K2E", "country": "US", "domain_rank": 408, "title": "BRIEF-Recipharm Signs Licensing Agreement with Altus Formulation", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.331, "site_type": "news", "published": "2018-03-05T17:06:00.000+02:00", "replies_count": 0, "uuid": "1f58883ac1f510d69db5f72d7278ca93e9768023"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-recipharm-signs-licensing-agreemen/brief-recipharm-signs-licensing-agreement-with-altus-formulation-idUSASM000K2E", "ord_in_thread": 0, "title": "BRIEF-Recipharm Signs Licensing Agreement with Altus Formulation", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "altus", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 5 (Reuters) - RECIPHARM AB (PUBL):\n* RECIPHARM AND ALTUS FORMULATION COLLABORATE TO OFFER NOVEL DRUG DELIVERY TECHNOLOGIES FOR VALUE ADDED MEDICINES\n* ‍HAS SIGNED A LICENSING AGREEMENT WITH ALTUS FORMULATION INC​\n* ‍SIGNED A LICENSING AGREEMENT WITH ALTUS FORMULATION INC.​\n* ‍ WILL CO-DEVELOP NEW VALUE ADDED MEDICINES FOR ITS CUSTOMERS UTILISING ALTUS’ PATENTED INTELLITAB™ AND FLEXITAB™ DRUG DELIVERY TECHNOLOGIES.​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-05T17:06:00.000+02:00", "crawled": "2018-03-06T22:37:25.041+02:00", "highlightTitle": ""}